Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effects of Cannabidiol in Alcohol Use Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03252756
Recruitment Status : Active, not recruiting
First Posted : August 17, 2017
Last Update Posted : March 11, 2022
National Institutes of Health (NIH)
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
The goal of the proposed project is to begin rigorous study of the clinically relevant effects of non-psychoactive phytocannabinoid cannabidiol (CBD) in patients with severe alcohol use disorder (AUD). This double-blind, randomized proof-of-concept study (n = 40) is designed to assess feasibility and contrast effects of extended (8 weeks) treatment with CBD to those of placebo in AUD patients. Participants with AUD will be randomized to receive either placebo or 600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks). These doses were chosen to reproduce serum CBD levels reported to reduce alcohol-seeking behavior in animal studies. Measures will include circulating levels of CBD, safety measures (THC serum levels, adverse events, cognitive and motoric function), and physiological and psychological domains relevant to AUD (including self-reported craving, depression, and anxiety, and responses to personalized scripts designed to elicit stress- and cue-induced craving and anxiety). Assessments will be conducted following 1 day, 1 week, and 4 weeks of treatment with each dose of CBD vs. placebo, and 1 and 4 weeks after the cessation of treatment. Drinking outcomes across 8 weeks of treatment and 4 weeks of follow-up will also be assessed as an exploratory outcome.

Condition or disease Intervention/treatment Phase
Alcohol Use Disorder Other: Placebo Drug: Phytocannabinoid cannabidiol (CBD) Phase 1 Phase 2

Detailed Description:
There is increasing recognition of the roles of the endocannabinoid system in neurobiological processes and behavioral domains relevant to addiction. The non-psychoactive phytocannabinoid cannabidiol (CBD) has attracted considerable attention due to its lack of abuse potential, its excellent safety profile, its unique and complex pharmacology, and evidence that it affects anxiety and stress response in animal models and humans. There is a growing body of preclinical data demonstrating that CBD produces marked and persisting decreases in alcohol self-administration and preference for alcohol, and alcohol-, cue- and stress-induced reinstatement of alcohol-seeking behavior, yet there are few studies of the effects of CBD in humans with addictive disorders, and none in alcohol dependent patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-blind, randomized proof-of-concept study
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Effects of Cannabidiol in Alcohol Use Disorder
Actual Study Start Date : September 1, 2019
Actual Primary Completion Date : February 23, 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Alcohol
Drug Information available for: Cannabidiol

Arm Intervention/treatment
Placebo Comparator: Placebo
600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
Other: Placebo
600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).

Experimental: Phytocannabinoid cannabidiol (CBD)
600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
Drug: Phytocannabinoid cannabidiol (CBD)
600mg CBD (PO) for 4 weeks, immediately followed by 1200mg CBD/ day (PO) for an additional 4 weeks (8 total weeks).

Primary Outcome Measures :
  1. Change in Time-line Follow-back (TLFB) assessment of alcohol consumption in Serum [ Time Frame: Baseline to 4 weeks ]
  2. Change in Percent carbohydrate deficient transferrin (CDT) assessment of alcohol consumption in Serum [ Time Frame: Baseline to 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females age 18-65
  • DSM-5 diagnosis of moderate or severe AUD
  • Able to provide voluntary informed consent
  • At least 8 heavy drinking days (4 or more drinks for a woman, 5 or more drinks for a man) in the 30 days prior to screen
  • If of childbearing potential (male or female), are willing to use approved form of contraception from screening for duration of the trial
  • Able to provide at least two locators
  • Endorse desire to cut down or stop drinking
  • Agrees to abstain from all other cannabinoid use for duration of the study

Exclusion Criteria:

  • Current alcohol withdrawal (CIWA-Ar score >7)
  • Exclusionary medical conditions (e.g. current severe alcohol withdrawal requiring medical hospitalization, significantly impaired liver function)
  • DSM-5 diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder
  • High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support)
  • Current significant suicidality (assessed using the C-SSRS), any suicidal behavior in the past 12 months, or any history of serious suicide attempts requiring hospitalization, or current significant homicidality
  • History of severe Traumatic Brain Injury (LOC > 24 hours)
  • DSM-5 diagnosis of current mild cannabis use disorder and/or moderate or severe substance use disorder for a substance other than alcohol or nicotine
  • Significant laboratory abnormalities, including significantly impaired liver function, serious abnormalities of complete blood count or metabolic panel
  • Active legal problems likely to result in incarceration within 12 weeks of treatment initiation
  • Pregnancy or lactation
  • Current use of exclusionary medications, including cannabinoids; treatments for addictions including alcohol; moderate to strong inhibitors of CYP3A4 or CYP2C19; medications metabolized primarily by CYP3A4, CYP3A5, or CYP3A7; and medications with a narrow therapeutic index which are substrates of UGT1A9, UGT2B7, CYP2C8, CYP2C9, CYP2C19, CYP1A2, or CYP2B6.
  • Allergy to any ingredient of the study compound.
  • Current treatment for AUD, with exception of AA/12-step treatment
  • No inpatient psychiatric treatment in the last 12 months, with the exception of detox and extended Emergency Department stays
  • A positive urine drug screen for THC, cocaine and/or opioids at screen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03252756

Layout table for location information
United States, New York
New York University School of Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Michael Bogenschutz, PhD NYU Langone Health
Layout table for additonal information
Responsible Party: NYU Langone Health Identifier: NCT03252756    
Other Study ID Numbers: 17-01001
First Posted: August 17, 2017    Key Record Dates
Last Update Posted: March 11, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Beginning 3 months and ending 5 years following article publication.
Access Criteria: Researchers who provide a methodologically sound proposal with have access to the data. To gain access, data requestors will need to sign a data access agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by NYU Langone Health:
Alcohol Use Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcohol Drinking
Pathologic Processes
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders